Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,180 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo tablets BID Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Apixaban in Recent Acute Coronary Syndrome

NCT00313300
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

NCT05511519
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
ATI-450, Placebo Oral Tablet
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Miami Lakes, Florida • Tampa, Florida • Freehold, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT03970837
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Tofacitinib, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
64
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional Results available

Maraviroc in Rheumatoid Arthritis

NCT00427934
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Maraviroc, Maraviroc Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Huntington Beach, California • San Francisco, California • Hamden, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

NCT05683249
View directory record Official record
Conditions
ADHD
Interventions
NRCT-101-SR, Placebo
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional Results available

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

NCT00570063
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-02545920, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Glendale, California • Lemon Grove, California • Paramount, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
CB-839, Cabozantinib, Placebo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY4268989 (MORF-057) in Healthy Participants

NCT06964776
View directory record Official record
Conditions
Healthy
Interventions
LY4268989, Placebo, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1, STP7 Cocaine Drug-Drug Interaction Study

NCT06273540
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
STP7 (mavoglurant), Placebo, Cocaine Hydrochloride
Drug
Lead sponsor
Stalicla SA
Industry
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT01626378
View directory record Official record
Conditions
Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions
TRx0237, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 79 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional Results available

Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

NCT01285310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Apremilast 30 mg, Apremilast 20 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 21, 2026, 2:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

NCT07656415
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mitapivat Matched Placebo, Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan • Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Garlic Supplements on Opioids in Healthy Volunteers

NCT00499460
View directory record Official record
Conditions
Healthy, No Evidence of Disease
Interventions
garlic powder tablets, oxycodone
Dietary Supplement · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

NCT03919162
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (MK-0518), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

NCT01736696
View directory record Official record
Conditions
Psoriasis, Immunomodulation
Interventions
tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 21, 2026, 2:23 PM EDT
Recruiting Phase 3 Interventional

Effect of Sacubitril-Valsartan on Cardiac Structure and Function

NCT06693674
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Entresto Pill, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 2:23 PM EDT
Recruiting Phase 4 Interventional

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

NCT06003348
View directory record Official record
Conditions
Calcium Phosphate Kidney Stones
Interventions
OHCit- standard dose, Potassium Citrate, Placebo, OHCit- low dose
Dietary Supplement · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

NCT01014585
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

NCT01356940
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dalfampridine ER, placebo
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162

NCT01691274
View directory record Official record
Conditions
Healthy
Interventions
PF-04895162, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 21, 2026, 2:23 PM EDT